KUMAMOTO University

R

研究業績RESEARCH ACHIEVEMENTS

  1. Okuno Y, Tatetsu H, Nosaka K, Mitsuya H.

    Three cases of aggressive natural killer cell leukemia with a lethal hemorrhagic complication.

    J Clin Exp Hematop. 2012;52(2):101-6. doi: 10.3960/jslrt.52.101. PMID: 23037625.

    https://pubmed.ncbi.nlm.nih.gov/23037625/

     

  2. Edwards CK 3rd, Green JS, Volk HD, Schiff M, Kotzin BL, Mitsuya H, Kawaguchi T, Sakata KM, Cheronis J, Trollinger D, Bankaitis-Davis D, Dinarello CA, Norris DA, Bevilacqua MP, Fujita M, Burmester GR.

    Combined anti-tumor necrosis factor-α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone.

    Front Immunol. 2012 Dec 4;3:366. doi: 10.3389/fimmu.2012.00366. PMID: 23264777; PMCID: PMC3525111.

    https://pubmed.ncbi.nlm.nih.gov/23264777/

     

  3. Kirby KA, Michailidis E, Fetterly TL, Steinbach MA, Singh K, Marchand B, Leslie MD, Hagedorn AN, Kodama EN, Marquez VE, Hughes SH, Mitsuya H, Parniak MA, Sarafianos SG.

    Effects of substitutions at the 4′ and 2 positions on the bioactivity of 4′-ethynyl-2-fluoro-2′-deoxyadenosine.

    Antimicrob Agents Chemother. 2013 Dec;57(12):6254-64. doi: 10.1128/AAC.01703-13. Epub 2013 Oct 7. PMID: 24100493; PMCID: PMC3837839.

    https://pubmed.ncbi.nlm.nih.gov/24100493/

     

  4. Aoki M, Danish ML, Aoki-Ogata H, Amano M, Ide K, Das D, Koh Y, Mitsuya H.

    Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1.

    J Virol. 2012 Dec;86(24):13384-96. doi: 10.1128/JVI.07234-11. Epub 2012 Sep 26. PMID: 23015723; PMCID: PMC3503118.

  5. Mizuhara T, Oishi S, Ohno H, Shimura K, Matsuoka M, Fujii N.

    Structure-activity relationship study of pyrimido[1,2-c][1,3]benzothiazin-6-imine derivatives for potent anti-HIV agents.

    Bioorg Med Chem. 2012 Nov 1;20(21):6434-41. doi: 10.1016/j.bmc.2012.08.030. Epub 2012 Aug 30. PMID: 23022280.

    https://pubmed.ncbi.nlm.nih.gov/23022280/

     

  6. Tanaka G, Nakase I, Fukuda Y, Masuda R, Oishi S, Shimura K, Kawaguchi Y, Takatani-Nakase T, Langel U, Gräslund A, Okawa K, Matsuoka M, Fujii N, Hatanaka Y, Futaki S.

    CXCR4 stimulates macropinocytosis: implications for cellular uptake of arginine-rich cell-penetrating peptides and HIV.

    Chem Biol. 2012 Nov 21;19(11):1437-46. doi: 10.1016/j.chembiol.2012.09.011. PMID: 23177198.

    https://pubmed.ncbi.nlm.nih.gov/23177198/

     

  7. Mizuhara T, Oishi S, Ohno H, Shimura K, Matsuoka M, Fujii N.

    Concise synthesis and anti-HIV activity of pyrimido[1,2-c][1,3]benzothiazin-6-imines and related tricyclic heterocycles.

    Org Biomol Chem. 2012 Sep 7;10(33):6792-802. doi: 10.1039/c2ob25904d. Epub 2012 Jul 24. PMID: 22829059.

    https://pubmed.ncbi.nlm.nih.gov/22829059/

     

  8. Gazon H, Lemasson I, Polakowski N, Césaire R, Matsuoka M, Barbeau B, Mesnard JM, Peloponese JM Jr.

    Human T-cell leukemia virus type 1 (HTLV-1) bZIP factor requires cellular transcription factor JunD to upregulate HTLV-1 antisense transcription from the 3′ long terminal repeat.

    J Virol. 2012 Sep;86(17):9070-8. doi: 10.1128/JVI.00661-12. Epub 2012 Jun 13. PMID: 22696638; PMCID: PMC3416116.

    https://pubmed.ncbi.nlm.nih.gov/22696638/

     

  9. Murphey-Corb M, Rajakumar P, Michael H, Nyaundi J, Didier PJ, Reeve AB, Mitsuya H, Sarafianos SG, Parniak MA.

    Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine in vitro and in vivo.

    Antimicrob Agents Chemother. 2012 Sep;56(9):4707-12. doi: 10.1128/AAC.00723-12. Epub 2012 Jun 19. PMID: 22713337; PMCID: PMC3421895.

    https://pubmed.ncbi.nlm.nih.gov/22713337/

     

  10. Kawano Y, Fujiwara S, Wada N, Izaki M, Yuki H, Okuno Y, Iyama K, Yamasaki H, Sakai A, Mitsuya H, Hata H.

    Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.

    Int J Oncol. 2012 Sep;41(3):876-84. doi: 10.3892/ijo.2012.1545. Epub 2012 Jul 4. PMID: 22766978; PMCID: PMC3582943.

    https://pubmed.ncbi.nlm.nih.gov/22766978/

     

  11. Li X, Qian H, Miyamoto F, Naito T, Kawaji K, Kajiwara K, Hattori T, Matsuoka M, Watanabe K, Oishi S, Fujii N, Kodama EN.

    A simple, rapid, and sensitive system for the evaluation of anti-viral drugs in rats.

    Biochem Biophys Res Commun. 2012 Jul 27;424(2):257-61. doi: 10.1016/j.bbrc.2012.06.097. Epub 2012 Jun 23. PMID: 22735265.

    https://pubmed.ncbi.nlm.nih.gov/22735265/

     

  12. Sohl CD, Kasiviswanathan R, Kim J, Pradere U, Schinazi RF, Copeland WC, Mitsuya H, Baba M, Anderson KS.

    Balancing antiviral potency and host toxicity: identifying a nucleotide inhibitor with an optimal kinetic phenotype for HIV-1 reverse transcriptase.

    Mol Pharmacol. 2012 Jul;82(1):125-33. doi: 10.1124/mol.112.078758. Epub 2012 Apr 18. PMID: 22513406; PMCID: PMC3382833.

    https://pubmed.ncbi.nlm.nih.gov/22513406/

     

  13. Maeda K, Das D, Nakata H, Mitsuya H.

    CCR5 inhibitors: emergence, success, and challenges.

    Expert Opin Emerg Drugs. 2012 Jun;17(2):135-45. doi: 10.1517/14728214.2012.673584. Epub 2012 Apr 25. PMID: 22533737.

    https://pubmed.ncbi.nlm.nih.gov/22533737/

     

  14. Satou Y, Utsunomiya A, Tanabe J, Nakagawa M, Nosaka K, Matsuoka M.

    HTLV-1 modulates the frequency and phenotype of FoxP3+CD4+ T cells in virus-infected individuals.

    Retrovirology. 2012 May 30;9:46. doi: 10.1186/1742-4690-9-46. PMID: 22647666; PMCID: PMC3403885.

    https://pubmed.ncbi.nlm.nih.gov/22647666/

     

  15. Masuda R, Oishi S, Tanahara N, Ohno H, Hirasawa A, Tsujimoto G, Kodama E, Matsuoka M, Fujii N.

    Development and application of fluorescent SDF-1 derivatives.

    Future Med Chem. 2012 May;4(7):837-44. doi: 10.4155/fmc.12.31. PMID: 22571609.

    https://pubmed.ncbi.nlm.nih.gov/22571609/

     

  16. Ghosh AK, Chapsal BD, Steffey M, Agniswamy J, Wang YF, Amano M, Weber IT, Mitsuya H.

    Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors.

    Bioorg Med Chem Lett. 2012 Mar 15;22(6):2308-11. doi: 10.1016/j.bmcl.2012.01.061. Epub 2012 Feb 2. PMID: 22364812; PMCID: PMC3433276.

    https://pubmed.ncbi.nlm.nih.gov/22364812/

     

  17. Sohl CD, Singh K, Kasiviswanathan R, Copeland WC, Mitsuya H, Sarafianos SG, Anderson KS.

    Mechanism of interaction of human mitochondrial DNA polymerase γ with the novel nucleoside reverse transcriptase inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine indicates a low potential for host toxicity.

    Antimicrob Agents Chemother. 2012 Mar;56(3):1630-4. doi: 10.1128/AAC.05729-11. Epub 2011 Dec 12. PMID: 22155823; PMCID: PMC3294915.

    https://pubmed.ncbi.nlm.nih.gov/22155823/

     

  18. Kiyasu J, Aoki R, Tanaka PY, Pracchia LF, Calore EE, Perez NM, Kimura Y, Niino D, Sugita Y, Takayanagi R, Abe Y, Matsuoka M, Ohshima K.

    FOXP3(+) regulatory and TIA-1(+) cytotoxic T lymphocytes in HIV-associated Hodgkin lymphoma.

    Pathol Int. 2012 Feb;62(2):77-83. doi: 10.1111/j.1440-1827.2011.02754.x. PMID: 22243776.

    https://pubmed.ncbi.nlm.nih.gov/22243776/

     

  19. Ghosh AK, Anderson DD, Weber IT, Mitsuya H.

    Enhancing protein backbone binding–a fruitful concept for combating drug-resistant HIV.

    Angew Chem Int Ed Engl. 2012 Feb 20;51(8):1778-802. doi: 10.1002/anie.201102762. Epub 2012 Jan 31. PMID: 22290878.

    https://pubmed.ncbi.nlm.nih.gov/22290878/

     

  20. Kawano Y, Ueno S, Abe M, Kikukawa Y, Yuki H, Iyama K, Okuno Y, Mitsuya H, Hata H.

    TRAIL produced from multiple myeloma cells is associated with osteolytic markers.

    Oncol Rep. 2012 Jan;27(1):39-44. doi: 10.3892/or.2011.1491. Epub 2011 Oct 6. PMID: 21993926.

    https://pubmed.ncbi.nlm.nih.gov/21993926/

     

  21. Sugata K, Satou Y, Yasunaga J, Hara H, Ohshima K, Utsunomiya A, Mitsuyama M, Matsuoka M.

    HTLV-1 bZIP factor impairs cell-mediated immunity by suppressing production of Th1 cytokines.

    Blood. 2012 Jan 12;119(2):434-44. doi: 10.1182/blood-2011-05-357459. Epub 2011 Nov 28. PMID: 22123848; PMCID: PMC3257009.

    https://pubmed.ncbi.nlm.nih.gov/22123848/

     

  22. Ndongwe TP, Adedeji AO, Michailidis E, Ong YT, Hachiya A, Marchand B, Ryan EM, Rai DK, Kirby KA, Whatley AS, Burke DH, Johnson M, Ding S, Zheng YM, Liu SL, Kodama E, Delviks-Frankenberry KA, Pathak VK, Mitsuya H, Parniak MA, Singh K, Sarafianos SG.

    Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase.

    Nucleic Acids Res. 2012 Jan;40(1):345-59. doi: 10.1093/nar/gkr694. Epub 2011 Sep 8. PMID: 21908397; PMCID: PMC3245923.

    https://pubmed.ncbi.nlm.nih.gov/21908397/

     

  23. Douceron E, Kaidarova Z, Miyazato P, Matsuoka M, Murphy EL, Mahieux R.

    HTLV-2 APH-2 expression is correlated with proviral load but APH-2 does not promote lymphocytosis.

    J Infect Dis. 2012 Jan 1;205(1):82-6. doi: 10.1093/infdis/jir708. Epub 2011 Nov 7. PMID: 22065675; PMCID: PMC3242747.

    https://pubmed.ncbi.nlm.nih.gov/22065675/

     

  24. Tatetsu H, Tenen DG, Chai L.

    The Interplay between Transcription Factor SALL4 and Histone Modifiers in Hematopoietic Stem and Progenitor Cells.

    J Cell Immunol 3(1):26-30.2021.   doi: 10.33696/immunology.3.073.

    https://pubmed.ncbi.nlm.nih.gov/33884376/

     

CONTACT US

C

  • 患者様へ

    外来診療の方は外来予約センターより
    ご予約をお願いいたします。
    外来予約センター

  • 学生・研修医・医療関係者の方へ

    TEL
    096-373-5156
    FAX
    096-373-5158
    Mail
    nikyo*kumamoto-u.ac.jp
    (*はアットマーク)
Copyright 2019 KUMAMOTO University HRI All Rights Reserved.